BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22406056)

  • 1. Intravascular ultrasound insights from the Cobalt Chromium Stent With Antiproliferative for Restenosis II (COSTAR II) trial comparing CoStar and Taxus paclitaxel-eluting stents.
    Tsujino I; Koizumi T; Shimohama T; Ako J; Waseda K; Krucoff M; Honda Y; Fitzgerald PJ
    Cardiovasc Revasc Med; 2012; 13(2):111-8. PubMed ID: 22406056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials.
    Doi H; Maehara A; Mintz GS; Yu A; Wang H; Mandinov L; Popma JJ; Ellis SG; Grube E; Dawkins KD; Weissman NJ; Turco MA; Ormiston JA; Stone GW
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1269-75. PubMed ID: 20129555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
    Waseda K; Miyazawa A; Ako J; Hasegawa T; Tsujino I; Sakurai R; Yock PG; Honda Y; Kandzari DE; Leon MB; Fitzgerald PJ;
    JACC Cardiovasc Interv; 2009 Aug; 2(8):779-84. PubMed ID: 19695548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravascular ultrasound results from the NEVO ResElution-I trial: a randomized, blinded comparison of sirolimus-eluting NEVO stents with paclitaxel-eluting TAXUS Liberté stents in de novo native coronary artery lesions.
    Otake H; Honda Y; Courtney BK; Shimohama T; Ako J; Waseda K; Macours N; Rogers C; Popma JJ; Abizaid A; Ormiston JA; Spaulding C; Cohen SA; Fitzgerald PJ
    Circ Cardiovasc Interv; 2011 Apr; 4(2):146-54. PubMed ID: 21386089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved strut coverage and less late incomplete apposition with thin-strut TAXUS Liberté vs. TAXUS Express: the importance of stent platform design for drug-eluting stents.
    Weissman NJ; Turco MA; Ormiston JA; Mann T; Cannon LA; McGarry TF; Webster MW; Hall JJ; Lucca MJ; Mishkel GJ; Wu CJ; Mandinov L; Dawkins KD
    Cardiovasc Revasc Med; 2011; 12(4):247-57. PubMed ID: 21130708
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study.
    Krucoff MW; Kereiakes DJ; Petersen JL; Mehran R; Hasselblad V; Lansky AJ; Fitzgerald PJ; Garg J; Turco MA; Simonton CA; Verheye S; Dubois CL; Gammon R; Batchelor WB; O'Shaughnessy CD; Hermiller JB; Schofer J; Buchbinder M; Wijns W;
    J Am Coll Cardiol; 2008 Apr; 51(16):1543-52. PubMed ID: 18420096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular responses to the multiple overlapped paclitaxel-eluting stents for the treatment of bare-metal in-stent restenotic lesions: angiographic and intravascular ultrasound analysis from the TAXUS-V ISR trial.
    Koizumi T; Fitzgerald PJ; Honda Y; Ellis SG; Kent K; Martin SL; Brown CL; Masud AR; Patterson JB; Greenberg J; Friedman M; Uchida T; Stone GW
    Cardiovasc Revasc Med; 2010; 11(3):140-8. PubMed ID: 20599163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of vascular response to the everolimus-eluting stent versus the paclitaxel-eluting stent: intravascular ultrasound results from the SPIRIT III trial.
    Yamasaki M; Tsujino I; Lima-Filho MO; Ako J; Shimohama T; Hasegawa T; Sakurai R; Sudhir K; Stone GW; Waseda K; Honda Y; Fitzgerald PJ
    EuroIntervention; 2012 Oct; 8(6):724-31. PubMed ID: 23086791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation: a serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial.
    Weissman NJ; Koglin J; Cox DA; Hermiller J; O'Shaughnessy C; Mann JT; Turco M; Caputo R; Bergin P; Greenberg J; Kutcher M; Wong SC; Strickland W; Mooney M; Russell ME; Ellis SG; Stone GW
    J Am Coll Cardiol; 2005 Apr; 45(8):1201-5. PubMed ID: 15837249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the polymer-based, paclitaxel-eluting TAXUS Express stent on vascular tissue responses: a volumetric intravascular ultrasound integrated analysis from the TAXUS IV, V, and VI trials.
    Weissman NJ; Ellis SG; Grube E; Dawkins KD; Greenberg JD; Mann T; Cannon LA; Cambier PA; Fernandez S; Mintz GS; Mandinov L; Koglin J; Stone GW
    Eur Heart J; 2007 Jul; 28(13):1574-82. PubMed ID: 17540849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic arterial responses to overlapping paclitaxel-eluting stents: insights from serial intravascular ultrasound analyses in the TAXUS-V and -VI trials.
    Aoki J; Mintz GS; Weissman NJ; Mann JT; Cannon L; Greenberg J; Grube E; Masud AR; Koglin J; Mandinov L; Stone GW
    JACC Cardiovasc Interv; 2008 Apr; 1(2):161-7. PubMed ID: 19463294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2.
    Chevalier B; Silber S; Park SJ; Garcia E; Schuler G; Suryapranata H; Koolen J; Hauptmann KE; Wijns W; Morice MC; Carrie D; van Es GA; Nagai H; Detiege D; Paunovic D; Serruys PW;
    Circ Cardiovasc Interv; 2009 Jun; 2(3):188-95. PubMed ID: 20031715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and angiographic outcomes after treatment of de novo coronary stenoses with a novel platinum chromium thin-strut stent: primary results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System) trial.
    Kereiakes DJ; Cannon LA; Feldman RL; Popma JJ; Magorien R; Whitbourn R; Dauber IM; Rabinowitz AC; Ball MW; Bertolet B; Kabour A; Foster MC; Wang JC; Underwood P; Dawkins KD
    J Am Coll Cardiol; 2010 Jul; 56(4):264-71. PubMed ID: 20493653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term impact of routinely detected early and late incomplete stent apposition: an integrated intravascular ultrasound analysis of the TAXUS IV, V, and VI and TAXUS ATLAS workhorse, long lesion, and direct stent studies.
    Steinberg DH; Mintz GS; Mandinov L; Yu A; Ellis SG; Grube E; Dawkins KD; Ormiston J; Turco MA; Stone GW; Weissman NJ
    JACC Cardiovasc Interv; 2010 May; 3(5):486-94. PubMed ID: 20488404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Cobalt chromium STent with Antiproliferative for Restenosis II (COSTAR II) trial study design: advancing the active-control evaluation of second-generation drug-eluting stents.
    Wang TY; Hasselblad V; Peterson JL; Wijns W; Parhizgar A; Kereiakes DJ; Krucoff MW
    Am Heart J; 2007 May; 153(5):743-8. PubMed ID: 17452147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct stenting with TAXUS stents seems to be as safe and effective as with predilatation. A post hoc analysis of TAXUS II.
    Silber S; Hamburger J; Grube E; Pfisterer M; Belardi J; Webb J; Zmudka K; Nienaber C; Hauptman K; Rutsch W; Dawkins K; Drzewiecki J; Koglin J; Colombo A
    Herz; 2004 Mar; 29(2):171-80. PubMed ID: 15057438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cobalt chromium stent with antiproliferative for restenosis trial in India (COSTAR I).
    Kaul U; Gupta RK; Mathur A; Dani S; Sapra R; Nayak PR; Lansky A; Cristea E; Carlier S; Gambone L; Litvack F
    Indian Heart J; 2007; 59(2):165-72. PubMed ID: 19122251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics of Late-Acquired Incomplete Stent Apposition: A Comparison With First-Generation and Second-Generation Drug-Eluting Stents.
    Waseda K; Ako J; Kume T; Fitzgerald PJ; Honda Y
    J Invasive Cardiol; 2016 Aug; 28(8):323-9. PubMed ID: 26689416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detailed intravascular ultrasound analysis of Zotarolimus-eluting phosphorylcholine-coated cobalt-chromium alloy stent in de novo coronary lesions (results from the ENDEAVOR II trial).
    Sakurai R; Hongo Y; Yamasaki M; Honda Y; Bonneau HN; Yock PG; Cutlip D; Popma JJ; Zimetbaum P; Fajadet J; Kuntz RE; Wijns W; Fitzgerald PJ;
    Am J Cardiol; 2007 Sep; 100(5):818-23. PubMed ID: 17719326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.